posted
Gap opening "In the context of general equities, opening price that is substantially higher or lower than the previous day's closing price, usually because of some extraordinarily positive or negative news." yahoo glossary definition.
IP: Logged |
posted
And don't take advice about when to buy or sell. I think this stock is looking pretty good right now. It may run again soon. Or it may not..do your own DD.
-------------------- "I will smack you in the mouth, I'm Neil Diamond"- Will Ferrell
IP: Logged |
posted
I'm just trying to save him some money, obviously he's doing his DD, what do you think he's doing when is questioning about some financial term? In fact, the market's strangling now.
IP: Logged |
posted
I knew he was doing DD, thats just how I sign off whenever I speak to someone that I perceive as a new investor. Its good advice always, not an insinuation of anything.
-------------------- "I will smack you in the mouth, I'm Neil Diamond"- Will Ferrell
IP: Logged |
posted
Not a big fan of this stock. I dont understand the industry. its fun to watch it roller coast though(I think thats how its spelled)
IP: Logged |
posted
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Finalizes Two Financings Totaling Over $13 Million
Friday September 8, 8:00 am ET Proceeds to Accelerate ACTC Programs for the Development of Novel Stem Cell Therapies Directed at a Broad Range of Diseases and Disorders
ALAMEDA, Calif.--(BUSINESS WIRE)--Sept. 8, 2006--Advanced Cell Technology, Inc. (OTCBB:ACTC - News), announced that it closed two financings generating approximately $13 million in cash.
ADVERTISEMENT The proceeds will enable continued development of the Company's proprietary technology platforms, including the recently announced ACTC technique to generate human embryonic stem cell while preserving the donor embryo's potential for continued development. Included in ACTC's priorities for use of proceeds are the three therapeutic programs currently targeted by ACTC for advancement into the human clinical trial phase. These priorities include therapies for treatment of degenerative eye disease, heart and vascular disease, and technology to regenerate skin damaged by wounds, burns and in surgical procedures.
On September 6, 2006, ACTC closed its previously announced exercise by existing investors of additional investment rights under the Company's existing debenture financing. ACTC issued amortizing convertible debentures in the full principal amount of $10,981,250 reflecting a discount rate of 20.3187% for an aggregate cash purchase price of $8,750,000. In connection with this financing, ACTC has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issuable upon conversion of the debentures and the exercise of the warrants.
The Company has also concluded the previously announced repricing of its existing $2.53 warrants. The warrant repricing transaction resulted in the exercise of warrants for 4,541,672 shares of the Company's common stock, generating proceeds to ACTC of approximately $4.3 million. As previously announced, replacement warrants identical in all respects to the exercised warrants, except for an adjusted strike price of $1.60, will be issued to the warrant holders that exercised their warrants in the warrant repricing transaction.
Additional details regarding both of the financings will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
"These financings demonstrate the confidence our current investors have in ACTC's research and technology and in our strategic vision to play a leadership role in the field of stem cell-based regenerative medicine," said William M. Caldwell IV, Chief Executive Officer of Advanced Cell Technology. "We expect the proceeds generated by these financings will fund preclinical studies and accelerate our progress to commencement of the clinical studies necessary to develop real treatments that tap the amazing promise of stem cell technology."
ACTC's timetables for the filing of its IND applications with the FDA are dependent upon the preclinical findings completed thus far and data generated in additional preclinical studies being conducted or planned by the Company.
ACTC will also continue to accelerate development of its proprietary technology platforms, including a method for accelerating the formation of stem cells, and a novel technique to develop new human embryonic stem cell lines while preserving the donor embryo's potential for normal development and life.
* ACTCellerate®: The Company invented its ACTCellerate® technology platform to speed differentiation of cells from human embryonic stem cells, thereby expanding potential products made from embryonic stem cell technology. * ACTC recently announced a novel technique to generate human embryonic stem cell lines from embryos while fully preserving the embryo's potential for life and development. In a paper published recently in the peer-reviewed scientific journal "Nature," ACTC scientists described their technique to generate human embryonic stem cells using a proven single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). PGD is a widely used practice used at in vitro fertilization (IVF) clinics to assess the genetic health of preimplantation embryos. To date, more than 1,500 healthy children have been born following the procedure, and live with their families today.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact:
Financial Dynamics Robert Stanislaro, 212-850-5657 (Media) or The Investor Relations Group James Carbonara, 212-825-3210 (Investors) or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
Source: Advanced Cell Technology, Inc.
IP: Logged |
posted
You guys will want to check out the AMK.V thread posted on this board. I think if anyone is looking for some wicked short- long term gains.. this Gold and Silver exploration and development corp is about to explode... do your own DD. Good luck to all who manage to actually get in.
i wanted to warn people, but i couldn't... because if enough people did show up and buy? the short-selling would not have mattered, and i didn't want to stop people from buying..
the only way to break a short is to have even more buyers...
does that make sense?
everybody go back and look at the chart..see how they did it...
it ran up in three hours and then they let it trickle down as they sold shares they didn't even have...
it stinks to high heaven and it's the MAIN reason i don't post picks anymore...
anybody that got caught on this should write letters to their Senators and Congressperson...
be specific, don't write a long letter.. try to make it unemotional...
watch how long it sits on the SHO list...
it's going up now.... maybe the shorts stopped?
read FILINGS if you are gonna hold for more than a daytrade...
-------------------- Don't envy the happiness of those who live in a fool's paradise.
IP: Logged |
posted
Doniboy, you should have invested in GLIF (of course in hindsight). You would have made loads of money with a buy at 0.028 when I had flagged it earlier in my Sep 6 message
IP: Logged |
posted
ACTC (.735) WiCell Research Institute and Advanced Cell Technology Offer to Distribute New Stem Cell Lines to U.S. Researchers; Agreement Subject to U.S. Federal Government Recognition and Funding of Cell Lines
Business Wire "US Press Releases "
MADISON, Wis. and ALAMEDA, Ca.--(BUSINESS WIRE)--Sept. 12, 2006--
The WiCell Research Institute (WiCell) and Advanced CellTechnology (OTCBB:ACTC) announced today an agreement, in principle, tocollaborate to jointly distribute to U.S. scientists a range of newcell lines. These stem cell lines would be produced using a recentlyannounced technique in the peer-reviewed journal Nature, provided thatthe United States federal government recognizes these new lines andfunds research utilizing them. Under their collaboration, agreed inprinciple between the parties, Advanced Cell Technology and WiCellhope to make the new stem cell lines readily available to U.S.scientists for medical research.
In its role as the National Stem Cell Bank, WiCell has taken aleadership role in providing cells to academic researchers byproviding a free license and training to scientists interested inpursuing this new technology. More than 350 academic research groupsare working with cells from WiCell. Under the agreement in principle,WiCell, a subsidiary of the Wisconsin Alumni Research Foundation(WARF), would distribute stem cell lines derived from Advanced CellTechnology's proprietary method, if approved by the President and theNational Institutes of Health.
"Provided that the federal government is willing to fund futurehuman embryonic stem cell research where it can be demonstrated thatthe embryo was not harmed, we will do our part in scaling up many newlines under Good Manufacturing Processes (GMP) guidelines and makingsuch lines available," stated William M. Caldwell, IV., ChiefExecutive Officer of Advanced Cell Technology. "We are well aware ofthe impact that delays in advancing new therapies can have on peoplein need of therapy and provided that the federal government advanceslegislation in an expeditious manner, we will make the derivation ofnew lines a company priority."
"Advanced Cell Technology's development is very encouraging,"stated Elizabeth Donley, Executive Director of WiCell. "We are hopefulthat future human embryonic stem cells created by this new process canbe approved for federal funding. Increasing the number of federallyfunded stem cell lines is essential for speeding the development ofthis important technology to treat many of human kind's most seriousdiseases and injuries. WiCell has agreements to distribute 13 of the21 lines currently available on the National Institutes of HealthRegistry. We will continue our effort to provide all lines that areeligible for federal funding."
About the WiCell Research Institute
The WiCell Research Institute is dedicated to expanding thefrontiers of science and medicine by unlocking the potential of stemcells. As a subsidiary of the Wisconsin Alumni Research Foundation anda supporting organization of the University of Wisconsin-Madison,WiCell conducts research, supports research at UW-Madison, hosts theNational Stem Cell Bank, provides training for scientists, and offerseducational outreach programs for K-12 students and the community.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applyingstem cell technology in the emerging field of regenerative medicine.The company operates facilities in Alameda, California and Worcester,Massachusetts. For more information about the company, please visithttp://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial andoperating results, future growth in research and development programs,potential applications of our technology, opportunities for thecompany and any other statements about the future expectations,beliefs, goals, plans, or prospects expressed by management constituteforward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Any statements that are notstatements of historical fact (including statements containing thewords "will," "believes," "plans," "anticipates," "expects,""estimates," and similar expressions) should also be considered to beforward-looking statements. There are a number of important factorsthat could cause actual results or events to differ materially fromthose indicated by such forward-looking statements, including: limitedoperating history, need for future capital, risks inherent in thedevelopment and commercialization of potential products, protection ofour intellectual property, and economic conditions generally.Additional information on potential factors that could affect ourresults and other risks and uncertainties are detailed from time totime in the company's periodic reports, including the report on Form10-QSB for the quarter ended June 30, 2006.
Forward-looking statements are based on the beliefs, opinions, andexpectations of the company's management at the time they are made,and the company does not assume any obligation to update itsforward-looking statements if those beliefs, opinions, expectations,or other circumstances should change.
Source: Advanced Cell Technology, Inc.
-------------------- ......in Psychiatry circles it's known as a "warning sign"
IP: Logged |
posted
Dip here. This stock is getting played heavily by flippers and day traders. You can't really blame them, but with all this good news I figure the stock should be much higher.
-------------------- "I will smack you in the mouth, I'm Neil Diamond"- Will Ferrell
IP: Logged |
Advanced Cell Technology Reports Visual Function Rescue in Animals Utilizing Human Embryonic Stem Cell-Derived Retinal Cells; Transplanted Cells Shown Capable of Rescuing Photoreceptor Cells in RCS Rats with Retinal Disease Advanced Cell Technology, Inc. (OTCBB: ACTC.OB) today announced that company scientists and their collaborators rescued visual function in rats through implantation of retinal pigment epithelial cells (RPE) derived from human embryonic stem (hES) cells. The study results were reported in a paper entitled "Human Embryonic Stem Cell-Derived Cells Rescue Visual Function in Dystrophic RCS Rats" published online today ahead of print in the Fall 2006 issue of the journal Cloning and Stem Cells.
In a series of several experiments, researchers generated RPE cells from 18 different hES cell lines. Cells derived from one of the NIH-approved cell lines were injected into RCS rats in an attempt to compensate for the photoreceptor cell loss caused by a genetic trait carried by such RCS rats. These animals lose their photoreceptor cells over several months following birth and are used to study conditions under which this loss, similar to that occurring in macular degeneration, can be prevented or treated.
In the study published in Cloning and Stem Cells, rats were injected with hES- derived RPE cells into the subretinal space of the eye at 21 days after their birth, an age at which photoreceptor degeneration has not yet occurred. As controls, some rats received injections of cell culture medium alone, or were not injected. Tests for visual function were performed at 60 and 90 days after birth, times at which loss of photoreceptor cells has produced characteristic vision deficits. As more fully described in the paper, test results of relative visual acuity demonstrated that animals receiving hES-derived RPE cells performed significantly better than cell culture medium treated or untreated controls. Treated animals showed a 50 percent improvement over medium-treated controls and a 100 percent improvement over untreated controls in visual performance. Visual acuity was approximately 70 percent of normal rats.
"One important advantage offered by hES-derived cells over other cells developed to mimic or replace lost retinal pigment epithelium is that they more closely resemble primary human RPEs," stated Raymond D. Lund, Ph.D., Professor at the Moran Eye Center, University of Utah Health Science Center, Salt Lake City and the study's lead author. "Another significant advantage of using these cells is that a range of lines can be derived allowing the opportunity to 'tissue match' donor cells with recipient, a real advantage given that RPE cells are highly immunogenic and susceptible to rejection without some form of immunosuppression."
"Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement cells for clinical studies," stated Robert Lanza, M.D., Vice President of Research & Scientific Development at ACTC and senior author of the paper. "All 18 human embryonic stem cell lines we studied reliably produced retinal cells that could potentially be used to treat retinal degenerative diseases, such as macular degeneration. We showed that these cells have the capacity to rescue visual function in animals that otherwise would have gone blind. Importantly, the cells did not appear to cause any unwanted pathological responses in the animals following transplantation."
"We are working to generate clinical grade RPE cells from human embryonic stem cells under controlled GMP conditions," said Irina Klimanskaya, Ph.D., Director of Stem Cell Biology at ACTC, and the author who initiated this work. "However, more research is still required to optimize their performance and to assure they are safe for clinical trials."
"We are encouraged by this data related to our retinal program and are focused on driving therapies to the clinic," stated William M. Caldwell IV, CEO of ACTC.
Other authors include Shaomei Wang, Toby Holmes, Bin Lu, N. Bischoff, and Sergej Girman of the Moran Eye Center; Rebeca Ramos-Kelsey of Advanced Cell Technology, and Yves Sauve of the Ophthalmology and Physiology Dept., University of Alberta, Edmonton.
About Advanced Cell Technology, Inc.
Advanced Cell Technology Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com..
-------------------- ......in Psychiatry circles it's known as a "warning sign"
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
